arrow
L

Lígia Yukie Sassaki

Universidade Estadual Paulista
H指数:19
被引数:1,825

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Vitamin D, vitamin D receptor gene polymorphisms, and inflammatory bowel disease outcomes: From molecular mechanisms to clinical application

维生素D、维生素D受体基因多态性与炎症性肠病结局:从分子机制到临床应用

2026-04-210
PRE
Real-World Comparative Effectiveness and Safety of Ustekinumab Versus Anti-TNF Agents as First- or Second-Line Biologics in Crohn's Disease: A Multicenter Observational Study

真实世界中,乌司木单抗相较于抗-TNF药物的作为克罗恩病的一线或二线生物制剂的疗效与安全性比较:一项多中心观察性研究

2025-12-010
PRE
Clinical effectiveness and safety of vedolizumab versus infliximab in biologic-naïve patients with ulcerative colitis: A comparative real-world multicentric observational study

维多珠单抗与英夫利昔单抗在未接受过生物治疗的溃疡性结肠炎患者中的临床有效性和安全性: 一项比较真实世界的多中心观察性研究

2025-10-010
OAAI
From gut to liver: Exploring the relationship between inflammatory bowel disease and metabolic dysfunction-associated steatotic liver disease

从肠道到肝脏:探索炎症性肠病与代谢功能障碍相关脂肪性肝病的关联

2025-09-270
PRE
Tofacitinib for ulcerative colitis in Brazil: a multicenter observational study on effectiveness and safety

托法替尼治疗溃疡性结肠炎的巴西研究:一项关于有效性和安全性的多中心观察性研究

2025-03-180
OA
Effectiveness, safety and predictors of response to vedolizumab as first- or second-line biological therapy in patients with ulcerative colitis: A real-world observational multicenter study.
2025-01-220
PRE
Comparative effectiveness and safety of ustekinumab versus anti-tumour necrosis Factor agents as first- or second-line biologics in Crohns disease: a real-world multicentric observational study
2025-01-220
PRE
P1176 Low serum albumin levels are associated with higher colectomy rates in patients with moderate-to-severe ulcerative colitis on tofacitinib
2025-01-220
PRE
Factors Associated with the Optimization of Biological Therapy in Crohn's Disease and Ulcerative Colitis: Insights from the National GEDIIB Patient Registry in Brazil
2025-01-220
PRE